NCT02031198View on ClinicalTrials.gov

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

AADvac1

Active immunization against pathological Alzheimer's disease tau protein

Trial Locations (4)

1090

Medizinische Universitat Wien, Vienna

5020

Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg

8036

Medizinische Universitat Graz, Graz

A-1220

Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders, Vienna

Sponsors
All Listed Sponsors
lead

Axon Neuroscience SE

INDUSTRY